Ivonescimab Plus Chemo Extends Squamous NSCLC Survival.
- In the news
Ivonescimab combined with chemotherapy improves overall survival in advanced squamous NSCLC, showing a significant benefit over existing immunotherapy-chemotherapy regimens in a Chinese trial.
- Why it matters: Improving treatment outcomes for advanced squamous NSCLC is critical, especially given the limited effectiveness of current therapies across diverse populations. Understanding whether this benefit applies broadly can influence global treatment standards.
- What they did: The study involved a clinical trial in China testing ivonescimab, a bispecific antibody targeting PD-1 and VEGF, combined with chemotherapy, and comparing it to standard immunotherapy-chemotherapy regimens.
- The result: Results demonstrated a notable survival advantage with ivonescimab plus chemotherapy, supporting its potential as a new treatment option, though further research is needed to confirm its efficacy across different patient populations.